About: Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis
Creator	Alqahtani, Jaber Oyelade, Tope Canciani, Gabriele
Source	Medline; PMC
abstract	The mortality and severity in COVID-19 is increased in patients with comorbidities. The aim of this study was to evaluate the severity and mortality in COVID-19 patients with underlying kidney and liver diseases. We retrieved data on the clinical features and primary composite end point of COVID-19 patients from Medline and Embase which had been released from inception by the April 16, 2020. The data on two comorbidities, liver diseases and chronic kidney disease, were pooled and statistically analysed to explain the associated severity and mortality rate. One hundred and forty-two abstracts were screened, and 41 full articles were then read. In total, 22 studies including 5595 COVID-19 patients were included in this study with case fatality rate of 16%. The prevalence of liver diseases and chronic kidney disease (CKD) were 3% (95% CI; 2–3%) and 1% (95% CI; 1–2%), respectively. In patients with COVID-19 and underlying liver diseases, 57.33% (43/75) of cases were severe, with 17.65% mortality, while in CKD patients, 83.93% (47/56) of cases were severe and 53.33% (8/15) mortality was reported. This study found an increased risk of severity and mortality in COVID-19 patients with liver diseases or CKD. This will lead to better clinical management and inform the process of implementing more stringent preventative measures for this group of patients.
has issue date	2020-05-15(xsd:dateTime)
bibo:doi	10.3390/tropicalmed5020080
bibo:pmid	32429038
has license	cc-by
sha1sum (hex)	3889f165ce789ee69442fbd2d5fd9d90e172758d
schema:url	https://doi.org/10.3390/tropicalmed5020080
resource representing a document's title	Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis
has PubMed Central identifier	PMC7345004
has PubMed identifier	32429038
schema:publication	Trop Med Infect Dis
resource representing a document's body	covid:3889f165ce789ee69442fbd2d5fd9d90e172758d#body_text
is schema:about of	named entity 'process' named entity 'cases' named entity 'comorbidities' named entity 'mortality' named entity 'evaluate' named entity 'This' named entity 'diseases' named entity 'Review' named entity 'CHRONIC KIDNEY DISEASE' named entity '1-2' named entity 'MEASURES' named entity 'TO EXPLAIN' named entity 'patients' named entity 'point' named entity 'mortality' named entity 'patients' named entity 'screened' named entity 'statistically' named entity 'diseases' named entity 'patients' named entity 'One' named entity 'COVID-19' named entity 'COVID-19' named entity 'liver' named entity 'COVID-19' named entity 'CKD' named entity 'cardiovascular diseases' named entity 'comorbidities' named entity 'GFR' named entity 'measures' named entity '8/15' named entity 'liver diseases' named entity 'Medline' named entity 'COVID-19' named entity '95% CI' named entity '95% CI' named entity 'COVID-19' named entity 'Meta-Analysis' named entity 'Kidney Diseases' named entity 'severe' named entity 'sample sizes' named entity 'COPD' named entity 'obesity' named entity 'alcohol' named entity 'CKD' named entity 'diabetes' named entity 'CKD' named entity 'inflammation' named entity 'COVID-19' named entity 'Stata' named entity 'follow-up' named entity 'extra point' named entity 'liver diseases' named entity 'immune function' named entity 'CKD' named entity 'electronic medical records' named entity 'SE15' named entity 'rate of mortality' named entity 'infection' named entity 'COVID-19' named entity 'angiotensin II' named entity 'morbidity' named entity 'COVID-19' named entity 'study population' named entity 'ACE2 receptor' named entity 'heterogeneity' named entity 'intubation' named entity 'comorbidities' named entity 'liver' named entity 'CKDs' named entity 'CKD' named entity 'liver diseases' named entity 'CKD' named entity 'comorbidities' named entity 'Liver Diseases' named entity '3, 4' named entity 'liver diseases' named entity 'World Health Organization' named entity 'COVID-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software